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Brief Technique ReportsTranscatheter valve-in-valve implantation for the treatment of
stentless aortic valve dysfunctionJosep Rode´s-Cabau, MD, FESC, Eric Dumont, MD, Daniel Doyle, MD, and Jeroˆme Lemieux, MD,
Quebec City, Quebec, CanadaVideo clip is available online.Reoperation for the treatment of stentless aortic valve dys-
function has been shown to be technically challenging and
associated with a high operative mortality.1 Transcatheter
aortic valve implantation (TAVI) is emerging as an alterna-
tive to surgical aortic valve replacement for the treatment
of patients with severe aortic stenosis who are considered
to be at very high or prohibitive surgical risk. However,
very few data exist on the use of TAVI for the treatment of
bioprosthesis dysfunction. In this report we describe the
use of TAVI for the treatment of stentless aortic bioprosthesis
dysfunction.
CLINICAL SUMMARY
An 84-year-old woman was admitted to our hospital be-
cause of pulmonary edema. She had a history of hyperten-
sion, diabetes, prior stroke, chronic renal failure, coronary
artery disease, peripheral vascular disease, and aortic valve
replacement with a 23-mm Freestyle valve (Medtronic,
Irvine, Calif) placed by using the subcoronary technique
13 years ago. Coronary angiographic analysis showed occlu-
sion of the right coronary artery, and aortographic analysis
demonstrated severe aortic regurgitation (Figure 1, A).
Doppler echocardiographic analysis showed the presence
of severe transvalvular aortic regurgitation (Figure 1, B
and C, and Video 1), a mean aortic gradient of 8 mm Hg,
and normal left ventricular ejection fraction. The patient
was declined for conventional surgical aortic valve replace-
ment (Society of Thoracic Surgeons score, 47.9%), and she
was then evaluated for TAVI. The presence of peripheral
vascular disease precluded a retrograde approach through
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The procedure was performed in the operating room by
a team of cardiac surgeons and interventional cardiologists
using techniques extensively detailed in previous reports
(Video 2).2 On the basis of an aortic annulus measurement
of 20 mm made by means of transesophageal echocardio-
graphic (TEE) analysis, a 23-mm Edwards SAPIEN valve
(Edwards Lifesciences, Inc, Irvine, Calif) was selected for
implantation. Because of the lack of appropriate angio-
graphic markers (no valve calcification and no radiopaque
markers in the Freestyle valve), the procedure was mainly
guided by TEE. After identifying the aortic bioprosthesis
by means of TEE (Figure 1, D), the Edwards SAPIEN valve
was positioned at the level of the bioprosthetic valve. The
hinge point of the anterior mitral leaflet was also used as
an anatomic marker for positioning the ventricular end of
the valve. Valve deployment was performed under rapid
pacing (Figure 2, A and B, and Video 3). Doppler echocar-
diographic analysis showed a mean residual aortic gradient
and aortic valve area of 17 mm Hg and 1.10 cm2, respec-
tively, and trivial central aortic regurgitation (Figure 2, C
and D, and Videos 4 and 5). The postoperative period was
uneventful, and the patient was discharged 7 days after the
procedure. At 1 month’s follow-up, the patient was in
New York Heart Association functional class II, and there
were no changes in the echocardiographic parameters.
DISCUSSION
Ng and colleagues3 reported the use of TAVI for the treat-
ment of a significant paravalvular leak in a patient with a Free-
style aortic bioprosthesis. The present case shows the
feasibility of treating a severe aortic regurgitation caused by
structural deterioration of a Freestyle aortic bioprosthesis by
using the transapical TAVI approach with the Edwards SA-
PIEN valve and represents 1 step further in the use of TAVI
for the treatment of stentless aortic valve dysfunction. To
date, TAVI has been limited to the treatment of severe calcific
aortic stenosis, and the presence of calcium has been consid-
ered a key factor in facilitating valve anchoring and avoiding
embolization. Wenaweser and associates4 reported the first
case of TAVI for the treatment of a dysfunctional stented aortic
bioprosthesis. However, TAVI for the treatment of stentless
bioprosthesis dysfunction is a more challenging procedure be-
cause of the lack of landing support (stent) for the anchoring of
the transcatheter valve. Also, the absence of radiopaque
markers makes the positioning of the transcatheter valveery c July 2010
FIGURE 1. Aortographic and transesophageal echocardiographic images before transcatheter aortic valve implantation. A, Aortographic image showing
severe aortic regurgitation. B, Transesophageal echocardiographic image (long-axis view) showing the severity of aortic regurgitation (white arrow). C,
Transesophageal echocardiographic image (short-axis view) showing the transvalvular origin of aortic regurgitation. D, Transesophageal echocardiographic
image (long-axis view) depicting the Freestyle aortic valve as an echodense linear structure parallel to the aortic wall (white arrow).
Brief Technique Reportsmuch more difficult. We have previously showed the role of
TEE in guiding TAVI procedures,5 and the present report pro-
vides further insight into the importance of such an imaging
technique for guiding TAVI procedures. In our experienceFIGURE 2. Procedural and postprocedural transesophageal echocardiographic a
eter aortic valve implantation by balloon inflation (thick white arrow) under rapid
the transcatheter valve (white arrow) after valve implantation. C and D, Transes
showing trivial aortic regurgitation (white arrows) after valve implantation.
The Journal of Thoracic and Cathe use of echocardiographic landmarks, such as the hinge
point of the mitral valve, and the possibility of visualizing
the stentless aortic valve with TEE played a major role in the
correct positioning of the transcatheter valve.nd fluoroscopic images. A, Echocardiographic image showing the transcath-
pacing (thin white arrow). B, Fluoroscopic image (posteroanterior view) of
ophageal echocardiographic images (C, long-axis view; D, short-axis view)
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Brief Technique ReportsIn conclusion, this report shows the feasibility of TAVI
for the treatment of structural deterioration of a stentless aor-
tic bioprosthesis, suggesting that TAVI might be further
considered for the treatment of this highly challenging sub-
set of patients. However, the efficacy and safety of this strat-
egy should be determined in prospective studies with a large
number of patients and long-term follow-up.
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Cardiovasc Surg. 2009 [Epub ahead of print].Balloon-guided, tapered, Polyflex stent guidance: An atraumatic
technique for successful stent placement through tight, rigid
airway stenosesMoishe Liberman, MD,a and John C. Wain, MD,b Montreal, Quebec, Canada, and Boston, MassBenign airway strictures are often effectively treated with se-
quential dilation. However, when this is not successful, or in
cases of frequent stricture recurrence, retrievable stenting
can relieve symptoms as well as allow for airway remodel-
ing, resulting in a less stenotic lumen. Anastomotic strictures
are often difficult to dilate owing to fibrosis and suture reac-
tion. Reoperation in these cases is often extremely challeng-
ing owing to the limited length of airway remaining after the
first operation. In these cases, we prefer to use silicone stents
after dilation to allow stricture remodeling. The Polyflexself-expanding polyester/silicone airway stent (Boston
Scientific, Boston, Mass) works well for these challenging
cases because it is completely covered, thin-walled, and
does not contain any metallic elements.
The main challenge with the Polyflex stent delivery sys-
tem is that it must be positioned through the area of stenosis.
This proves to be extremely difficult in some strictures ow-
ing to the inflexibility of the stenosis and the blunt, rigid,
stent insertion system (Figure 1). The stent delivery device
is nondeformable in its undeployed state and requires inter-
nal stenting to permit atraumatic passage through some stric-
tures. To circumvent this, we insert a pulmonary balloon
dilator (CRE pulmonary balloon dilator; Boston Scientific)
through the delivery system and then through the stent.
The balloon is inflated with the tip protruding from the deliv-
ery system by approximately 10 mm (Figure 2, A). The bal-
loon acts as a tapered tip for the stent delivery system and
allows the delivery system to easily traverse the stenosis
without traumatizing it. The balloon is guided down to andFIGURE 1. The Polyflex stent delivery system.
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